MindBio Therapeutics
a multi-award-winning global leader in developing psychiatric medicines using microdoses of psychedelics. Currently in multiple world first take home Phase 2 clinical trials.
Featured Updates
We have been featured in:
Microdosing
There is a growing microdosing subculture and grey literature suggesting that this practice can enhance creativity and productivity, improve mood and favourably modify personality traits.
These claimed effects are similar to those observed in clinical studies, in which participants receive much larger, perception-altering doses of LSD or psilocybin. However, there were no controlled, scientific studies of the psychological or physiological effects of repeated psychedelic home-self-administered microdosing… until we conducted such a study…
Clinical Trials
Our clinical trials focusing on microdosing psychedelic medicines provides hope for sufferers of mental health conditions. As a new emerging treatment alternative, LSD is a promising agent for treating Major Depressive Disorder (MDD) . Our scientific research collaborators are working on a Phase 2 clinical trial microdosing MB22001 in patients with MDD and a Phase 2 clinical trial microdosing MB22001 in late stage cancer patients.
A randomised, double-blind, placebo-controlled trial to study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males.
Ongoing Updates
We are constantly providing updates on mental health practices and the progress of our work in providing solutions for sufferers of mental health conditions.
These updates are provided to our investors and subscribers to our update emails.
If you would like to receive these updates,
Awarded:
Company of the Year
— Annual Microdose Awards, Miami 2022
A brighter future for mental health.
— MindBio Therapeutics mission
“Phase 1 Clinical Trials are completed and we are happy to report positive topline data.”
— Justin Hanka, Co-Founder and Director, MindBioTherapeutics
“MindBio is pleased to announce that the first ten clinical trial participants (out of a total of 20 anticipated participants) with depression have started take home dosing of MB22001 in the Company’s Phase 2a clinical trial..”
— Justin Hanka, Co-Founder and Director, MindBioTherapeutics
SmallCap Investor interviews CEO Justin Hanka.
MindBio Therapeutics CEO Justin Hanka is interviewed by Joe Brunner. The interview is in English but note that the opening 66 seconds of show begins in German.
MindBio Therapeutics Co-founder Justin Hanka is interviewed by Joe Brunner at Smallcap Investor in Europe.
MindBio is listed on the CSE
Watch the InvestmentPitch Media video announcing the public listing of MindBio Therapeutics on the Canadian Stock Exchange on 5 May 2023. MindBio is trading. More here.
Announcing MindBio’s listing on the CSE
A fascinating history of LSD in Medicine.
Watch our short explainer film regarding the fascinating history of LSD in medicine and how psychedelics act to change the way the brain works.
A fascinating history of LSD in medicine
Meet our team
Gavin Upiter. BEng. (Chairman), is a serial pharmaceutical entrepreneur with over 25 years experience in the industry. Prior to founding Generic Health, a leading generic pharmaceutical company which was sold to Lupin Pharmaceuticals, (NSE: LUPIN), Gavin started his executive career at Bristol Myers Squibb. He was Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) and Executive Director of Slade Health, Australia’s leading hospital pharmacy chain. Gavin founded Directo, Australia’s first online pharmaceutical B2B marketplace for pharmacies and suppliers.
Dr Zena Burgess (Non executive director ) has over 25 years experience working in mental health areas as a clinical and organizational psychologist . She has also worked as an executive and consultant in the health industry. Zena is former CEO of the Royal Australian College of General Practitioners ( RACGP) and is currently CEO of the Australian Psychological Society( APS) which is the peak organisation for psychologists in Australia. She has been recognised by Fellowships of AICD and APS.
Justin Hanka (Co-Founder & Chief Executive Officer) is an investment banker with expertise in M&A and capital markets transactions & IPO’s in Australia and Nth America. He is Non-Executive Director of EonX (CSE: EONX), a financial technology company, Non-Executive Chair of SPARC AI Inc (CSE:SPAI) Non-Executive Chairman of Blackhawk Growth Corp (CSE: BLR) and Co-Founder of Merchant Bank Hardenbrook Group and multiple portfolio companies. Justin was recently voted Entrepreneur of the Year and Innovator of the Year at the leading industry awards.
“Mood disorders are a leading cause of health loss, however current treatments do not work or are not well tolerated by large numbers of people who suffer.”
— Health Research Council of New Zealand. Grant Summary of Purpose.